

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcement of The United Laboratories International Holdings Limited (the “Company”) of today’s date in relation to positive profit alert.

Due to clerical error, the units of certain figures in the Chinese announcement are incorrect and should be corrected as follows:

- the Group is expected to record a significant increase in profit for the year 2018 of not less than RMB650 million.
- the fair value change of embedded derivative components of convertible bonds records a gain of approximately RMB220 million.
- substantial decrease in loss on fair value change on investment properties of approximately RMB230 million.

There is no such error in the English announcement.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
**The United Laboratories
International Holdings Limited**
Tsoi Hoi Shan
Chairman

Hong Kong, 21 March 2019

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Ms. Zou Xian Hong, Ms. Zhu Su Yan and Mr. Fang Yu Ping as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.